Study wrapper · #522
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.
Editor's note
This is a focused biomarker analysis nested within a randomized, double-blind, placebo-controlled trial (61 participants) of tesamorelin in HIV-associated NAFLD. Researchers reported that tesamorelin was associated with significant reductions in three plasma proteins — VEGFA, TGFB1, and CSF1 — tied to angiogenesis, fibrosis, and inflammation, and that declines in VEGFA and CSF1 correlated with improvement in NAFLD activity score, while TGFB1 and CSF1 declines correlated with a reduced fibrosis gene score. This is mechanistic, hypothesis-generating work that plausibly explains the anti-fibrotic effects seen in the parent trial; the sample is small and the proteins are intermediate markers, not clinical endpoints. It adds supportive mechanistic weight to tesamorelin's liver effects in this population.
Plain-language abstract
This study looked at blood proteins to understand how tesamorelin affects the liver in people with HIV and fatty liver disease. Drawing on a randomized, double-blind, placebo-controlled trial, researchers measured nine proteins linked to blood-vessel growth, tissue scarring, and inflammation. Compared with placebo, tesamorelin was associated with lower levels of three of them — VEGFA, TGFB1, and CSF1. Among people taking tesamorelin, larger drops in some of these proteins went hand in hand with better scores for liver inflammation and scarring. The authors highlight CSF1, which helps recruit immune cells, as a possible target for future fatty-liver treatments. Because this examined intermediate blood markers in a small group rather than long-term liver outcomes, it helps explain how tesamorelin might work on the liver rather than proving a clinical benefit on its own.